{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:41:55Z","timestamp":1791981715495,"version":"4.4.0"},"reference-count":15,"publisher":"e-Century Publishing Corporation","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Exp Pathol"],"DOI":"10.62347\/zqci9925","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T02:04:42Z","timestamp":1712109882000},"page":"78-82","source":"Crossref","is-referenced-by-count":4,"title":["Post-therapeutic squamous cell transformation of a metastatic prostate adenocarcinoma with comparison of molecular profiles: a case report and review of the literature"],"prefix":"10.62347","volume":"17","author":[{"given":"Peizi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Lee CH, Akin-Olugbade O and Kirschenbaum A. Overview of prostate anatomy, histology, and pathology. Endocrinol Metab Clin North Am 2011; 40: 565-75, viii-ix.","DOI":"10.1016\/j.ecl.2011.05.012"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3390\/cancers15020461","article-title":"Metastatic prostate cancer-a review of current treatment options and promising new approaches","volume":"15","author":"Posdzich","year":"2023","unstructured":"Posdzich P, Darr C, Hilser T, Wahl M, Herrmann K, Hadaschik B and Grünwald V. Metastatic prostate cancer-a review of current treatment options and promising new approaches. Cancers (Basel) 2023; 15: 461.","journal-title":"Cancers (Basel)"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE and Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022; 72: 7-33.","journal-title":"CA Cancer J Clin"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/pros.22742","article-title":"Distribution of metastatic sites in patients with prostate cancer: a population-based analysis","volume":"74","author":"Gandaglia","year":"2014","unstructured":"Gandaglia G, Abdollah F, Schiffmann J, Trudeau V, Shariat SF, Kim SP, Perrotte P, Montorsi F, Briganti A, Trinh QD, Karakiewicz PI and Sun M. Distribution of metastatic sites in patients with prostate cancer: a population-based analysis. Prostate 2014; 74: 210-6.","journal-title":"Prostate"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.36401\/JIPO-22-4","article-title":"Oligometastatic squamous cell transformation from metastatic prostate adenocarcinoma treated with systemic and focal therapy: a case report","volume":"5","author":"Autio","year":"2022","unstructured":"Autio K and McBride S. Oligometastatic squamous cell transformation from metastatic prostate adenocarcinoma treated with systemic and focal therapy: a case report. J Immunother Precis Oncol 2022; 5: 79-83.","journal-title":"J Immunother Precis Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1746-1596-6-46","article-title":"Diagnostic dilemmas of squamous differentiation in prostate carcinoma case report and review of the literature","volume":"6","author":"Arva","year":"2011","unstructured":"Arva NC and Das K. Diagnostic dilemmas of squamous differentiation in prostate carcinoma case report and review of the literature. Diagn Pathol 2011; 6: 46.","journal-title":"Diagn Pathol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.euf.2021.04.003","article-title":"Overall survival after systemic treatment in high-volume versus low-volume metastatic hormone-sensitive prostate cancer: systematic review and network meta-analysis","volume":"8","author":"Wenzel","year":"2022","unstructured":"Wenzel M, Würnschimmel C, Nocera L, Collà Ruvolo C, Tian Z, Shariat SF, Saad F, Briganti A, Tilki D, Graefen M, Kluth LA, Roos FC, Mandel P, Chun FKH and Karakiewicz PI. Overall survival after systemic treatment in high-volume versus low-volume metastatic hormone-sensitive prostate cancer: systematic review and network meta-analysis. Eur Urol Focus 2022; 8: 399-408.","journal-title":"Eur Urol Focus"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1159557","DOI":"10.3389\/fonc.2023.1159557","article-title":"PARP inhibitors in metastatic prostate cancer","volume":"13","author":"Taylor","year":"2023","unstructured":"Taylor AK, Kosoff D, Emamekhoo H, Lang JM and Kyriakopoulos CE. PARP inhibitors in metastatic prostate cancer. Front Oncol 2023; 13: 1159557.","journal-title":"Front Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1001\/jamaoncol.2020.7857","article-title":"Association of bone metastatic burden with survival benefit from prostate radiotherapy in patients with newly diagnosed metastatic prostate cancer: a secondary analysis of a randomized clinical trial","volume":"7","author":"Ali","year":"2021","unstructured":"Ali A, Hoyle A, Haran ÁM, Brawley CD, Cook A, Amos C, Calvert J, Douis H, Mason MD, Dearnaley D, Attard G, Gillessen S, Parmar MKB, Parker CC, Sydes MR, James ND and Clarke NW. Association of bone metastatic burden with survival benefit from prostate radiotherapy in patients with newly diagnosed metastatic prostate cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol 2021; 7: 555-563.","journal-title":"JAMA Oncol"},{"key":"ref9","unstructured":"Okamoto T, Ogiu K, Sato M, Kaneko T, Suzuki Y, Tanji S and Fujioka T. Primary squamous cell carcinoma of the prostate: a case report. Hinyokika Kiyo 1996; 42: 67-70."},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Al-Qassim Z, Mohammed A, Payne D, Stocks PJ and Khan Z. Squamous cell carcinoma of the prostate following treatment with an LHRH-agonist: a rare case of transformation of adenocarcinoma of the prostate. Cent European J Urol 2014; 67: 26-8.","DOI":"10.5173\/ceju.2014.01.art5"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/j.1365-2559.1990.tb00738.x","article-title":"Squamous cell carcinoma of the prostate","volume":"17","author":"Wernert","year":"1990","unstructured":"Wernert N, Goebbels R, Bonkhoff H and Dhom G. Squamous cell carcinoma of the prostate. Histopathology 1990; 17: 339-44.","journal-title":"Histopathology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1159\/000519861","article-title":"Metastatic prostate cancer: treatment options","volume":"100","author":"Achard","year":"2022","unstructured":"Achard V, Putora PM, Omlin A, Zilli T and Fischer S. Metastatic prostate cancer: treatment options. Oncology 2022; 100: 48-59.","journal-title":"Oncology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.eururo.2018.02.001","article-title":"Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies","volume":"73","author":"Gravis","year":"2018","unstructured":"Gravis G, Boher JM, Chen YH, Liu G, Fizazi K, Carducci MA, Oudard S, Joly F, Jarrard DM, Soulie M, Eisenberger MJ, Habibian M, Dreicer R, Garcia JA, Hussain MHM, Kohli M, Vogelzang NJ, Picus J, DiPaola R and Sweeney C. Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies. Eur Urol 2018; 73: 847-855.","journal-title":"Eur Urol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.2217\/fon-2020-1133","article-title":"KEYNOTE-921: phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer","volume":"17","author":"Petrylak","year":"2021","unstructured":"Petrylak DP, Ratta R, Gafanov R, Facchini G, Piulats JM, Kramer G, Flaig TW, Chandana SR, Li B, Burgents J and Fizazi K. KEYNOTE-921: phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer. Future Oncol 2021; 17: 3291-3299.","journal-title":"Future Oncol"}],"container-title":["International Journal of Clinical and Experimental Pathology"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ijcep\/17\/3\/ijcep0153981.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:52:12Z","timestamp":1766022732000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ijcep\/17\/3\/ijcep0153981.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":15,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.62347\/zqci9925","relation":{},"ISSN":["1936-2625"],"issn-type":[{"value":"1936-2625","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]}}}